Antibodies against human and canine IL-13RA2
AssigneeWake Forest University Health Sciences
InventorsWaldemar Debinski, Denise Mazess Herpai
Life of this patent
Estimating the term…
Abstract
Provided herein are monoclonal antibodies that specifically bind IL-13RA2 with cross-reactivity in humans and canines. Also provided are methods of use of the antibodies in the treatment and monitoring of cancers.
Claims30
A method of treating a tumor in a subject in need thereof comprising administering to said subject in a treatment effective amount an antibody that specifically binds an epitope within amino acids spanning the extracellular portion of human IL-13RA2, wherein said epitope is within amino acids spanning the extracellular portion of human IL-13RA2 that have at least 90% identity with the corresponding canine sequence of IL-13RA2, and wherein said antibody is coupled to a chemotherapeutic agent,
- wherein said epitope is within amino acids of SEQ ID NO:
- 1 (Peptide 1);
- SEQ ID NO:
- 2 (Peptide 2);
- or SEQ ID NO:
- 3 (Peptide 3),
- wherein said antibody comprises a variable light chain amino acid sequence of SEQ ID NO:8 or at least 95% identity thereto, and a variable heavy chain amino acid sequence of SEQ ID NO:10 or at least 95% identity thereto, and
- wherein said antibody specifically binds to both human and canine IL-13RA.
A method of inhibiting cancer metastasis in a subject in need thereof comprising administering to said subject in a treatment effective amount an antibody that specifically binds an epitope within amino acids spanning the extracellular portion of human IL-13RA2, wherein said epitope is within amino acids spanning the extracellular portion of human IL-13RA2 that have at least 90% identity with the corresponding canine sequence of IL-13RA2, and wherein said antibody is coupled to a chemotherapeutic agent,
- wherein said epitope is within amino acids of SEQ ID NO:
- 1 (Peptide 1);
- SEQ ID NO:
- 2 (Peptide 2);
- or SEQ ID NO:
- 3 (Peptide 3),
- wherein said antibody comprises a variable light chain amino acid sequence of SEQ ID NO:8 or at least 95% identity thereto, and a variable heavy chain amino acid sequence of SEQ ID NO:10 or at least 95% identity thereto, and
- wherein said antibody specifically binds to both human and canine IL-13RA.
Dependencies are inferred from the claim text.